Related Experiment Video

Updated: Sep 23, 2026

SDS-PAGE/Immunoblot Detection of Aβ Multimers in Human Cortical Tissue Homogenates using Antigen-Epitope Retrieval
10:48

SDS-PAGE/Immunoblot Detection of Aβ Multimers in Human Cortical Tissue Homogenates using Antigen-Epitope Retrieval

Published on: April 23, 2010

Alzheimer's disease and soluble A beta

T Wisniewski1, J Ghiso, B Frangione

  • 1Department of Pathology, New York University Medical Center, NY 10016.

Neurobiology of Aging
|March 1, 1994
PubMed

Insights

Soluble amyloid beta (sAβ) discovery changes Alzheimer's disease (AD) understanding, suggesting roles beyond initial membrane damage. Further research into sAβ structure is crucial for understanding AD pathogenesis.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pathology

Background:

  • Alzheimer's disease (AD) pathogenesis is complex, involving amyloid beta (Aβ) accumulation.
  • The discovery of soluble Aβ (sAβ) challenges the view of membrane damage as the primary AD event.
  • Aβ accumulation results from conformational changes in a normal peptide, resisting degradation.

Purpose of the Study:

  • To re-evaluate the role of amyloid in Alzheimer's disease.
  • To investigate the structural differences between soluble Aβ and deposited Aβ.
  • To identify factors influencing sAβ aggregation and its potential toxicity.

Main Methods:

  • Comparative structural analysis of soluble Aβ and amyloid deposits.
  • Investigation of genetic and environmental factors in AD.
  • Exploration of protein interactions, including molecular chaperones like apolipoprotein E.

Main Results:

  • Soluble Aβ suggests a role similar to systemic amyloidoses, differing from initial membrane damage theories.
  • Abnormal accumulation of Aβ is linked to conformational changes preventing proteolysis.
  • Mutations in the beta-amyloid precursor protein (βPP) gene are implicated in a small fraction of AD cases.

Conclusions:

  • The role of amyloid in AD may be analogous to systemic amyloidoses.
  • Understanding structural differences in Aβ is key to determining aggregation factors.
  • Structural alterations in Aβ and interactions with proteins like apolipoprotein E may drive neurotoxicity in AD.

More Related Videos

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy06:27

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy

Published on: November 30, 2018

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...